Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011

Presse Medicale

Volumn 40, Issue 4, 2011, Pages

  Benveniste, Olivier ^a,b   Léger, Jean Marc ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; IMMUNOGLOBULIN; METHOTREXATE;

ANTIBODY TITER; AUTOIMMUNE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; INTERSTITIAL LUNG DISEASE; MUSCLE STRENGTH; MYOSITIS; POLYMYOSITIS; PROTEIN EXPRESSION; SHORT SURVEY; UPREGULATION;

EID: 79953774874     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.02.002     Document Type: Short Survey

References (16)

1. Hilton-Jones D. Observations on the classification of the inflammatory myopathies. Presse Med 2011, 40:e199-e208.
2. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
3. Gherardi R.K. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 2011, 40:e209-e218.
4. Askanas V., Engel W.K. Sporadic inclusion-body myositis: conformational multifactorial aging-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med 2011, 40:e219-e235.
5. Dalakas M.C. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 2011, 40:e237-e247.
6. Benveniste O., Romero N.B. Myositis or dystrophy? Traps and pitfalls. Presse Med 2011, 40:e249-e255.
7. Hoogendijk J.E., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
8. Christopher-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
9. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2010; doi:10.1002/art.30156.
10. Targoff I.N., Mamyrova G., Trieu E.P., Perurena O., Koneru B., O'Hanlon T.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
11. Selva-O'Callaghan A., Trallero-Araguas E., Grau-Junyent J.M., Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010, 22:627-632.
12. Sato S., Hirakata M., Kuwana M., Suwa A., Inada S., Mimori T., et al. Autoantibodies to a 140-kd polypeptide. CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005, 52:1571-1576.
13. Hoshino K., Muro Y., Sugiura K., Tomita Y., Nakashima R., Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010, 49:1726-1733.
14. Marie I. Therapy of polymyositis and dermatomyositis. Presse Med 2011.
15. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M.G. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop. London, 13 June 2008. Neuromuscul Disord 2010, 20:142-147.
16. Benveniste O., Hilton-Jones D. International workshop on inclusion body myositis held at the Institute of Myology. Paris, on 29 May 2009. Neuromuscul Disord 2010, 20:414-421.